Dr Ula: Peptides in New Zealand: What they are, what’s available, and our clinical position
- 5 hours ago
- 3 min read
We are receiving more enquiries about peptides than ever before.
People are asking:
Can you prescribe them?
Are they legal in New Zealand?
Do they work?
Are they safe?
The word “peptide” is being used broadly, and often loosely. So it’s worth bringing clarity to the conversation.
What are Peptides?
Peptides are short chains of amino acids. Many of your natural hormones are peptides — insulin, GLP-1, growth hormone–releasing hormone.
In medicine, synthetic peptides can be developed to mimic or influence these signalling pathways.
Some of these are well-studied prescription medicines. Others are experimental compounds being marketed well ahead of strong human evidence.
They are not the same thing.
What is available in New Zealand?
In New Zealand, medicines are regulated by Medsafe.
There are peptide-based medicines that are fully approved and prescribed here, for example, GLP-1 receptor agonists used in diabetes and weight management. These have:
Large human clinical trials
Defined dosing
Known side effect profiles
Pharmaceutical manufacturing standards
Ongoing safety monitoring
That is evidence-based pharmacology.
There are also peptides discussed online, often promoted for fat loss, injury recovery, muscle gain, sleep or “anti-ageing.” Many of these:
Have promising animal studies
Have small or early human trials
Lack long-term safety data
Are not approved medicines in New Zealand
Some may be accessed under specific unapproved medicine provisions, but that is not the same as being approved, widely studied, or routinely recommended.
The key distinction is not whether something is “available.” It is whether it is evidence-based, regulated, and appropriate.
What does the evidence actually show?
For approved peptide medicines, the evidence is strong within specific indications.
For example, GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro) have been studied in thousands of patients over years. We understand their metabolic effects, cardiovascular implications, and side effect profile.
For many other peptides currently trending in wellness circles, the evidence is:
Early stage
Small sample size
Short duration
Limited safety data
That does not mean research will not evolve. It means that at present, the evidence base is limited.
In medicine, promising mechanism does not equal proven outcome.
Our clinical position at Autonomy
We are not anti-peptide. We are anti-hype.
Where there is strong human data, regulatory oversight, and a clear clinical indication, peptide-based medicines can have a legitimate role.
We do not prescribe experimental peptides without robust safety data, regulated supply pathways, and a defined monitoring framework.
Most importantly, we do not treat peptides as a shortcut.
They are tools, and tools only work within stable systems.
The systems question most people miss
Peptides influence signalling pathways, metabolism, inflammation, recovery, appetite, growth hormone axes.
But those same pathways are heavily influenced by:
Sleep quality and timing
Glucose stability
Alcohol exposure
Stress physiology
Resistance training and muscle mass
If those foundations are unstable, adding a peptide rarely creates durable results.
Often, it produces temporary shifts without correcting the underlying drivers.
In clinic, we frequently see individuals looking for advanced interventions when the primary constraint is physiological regulation.
This is not a dismissal of innovation.
It is recognition of hierarchy.
Biology responds to environment first.
So should you consider Peptides?
The better questions are:
What problem are we actually trying to solve?
What objective data supports using this intervention?
Is the product regulated and quality-controlled?
What markers will we measure to assess benefit and risk?
Have foundational drivers been stabilised first?
If those questions are answered clearly, peptide-based therapies may have a role in specific cases.
If they are not, caution is appropriate.
The bottom line
Peptides are neither miracle cures nor inherently dangerous.
Some are well-studied medicines with defined benefits.
Others remain experimental and marketed with more confidence than evidence.
Our role is not to chase trends.
It is to apply evidence carefully, measure objectively, and protect long-term health.
Clarity first. Then deliberate action.
A sensible next step
If you’re considering peptide therapy and want to understand whether it’s appropriate for your physiology and goals, a structured clinical review is the right place to start.
Dr. Ula
Co-Founder and Lead Physician, Autonomy
